Meta-analysis of 11 phase 3 trials (6035 patients) with HR-positive, HER2-negative advanced breast cancer: CDK4/6 inhibitors plus endocrine therapy improved PFS and OS vs endocrine therapy alone; only abemaciclib and ribociclib showed significant OS benefit.
Meta-analysisn = 6,035
Beshr et al. CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials